EGFRvIII CAR / National Cancer Institute, Gilead - LARVOL DELTA

Comprehensive evaluation of CAR-engineered immune cell subsets reveals therapeutic synergy in an immune-competent glioblastoma model (EANO 2025) - "Recent efforts have focused on leveraging alternative immune cell types for CAR engineering, but a systematic side-by-side comparison in an immune-competent glioma model has been lacking.Material and To address this, we developed a transgenic mouse strain on a C57BL/6 background harboring an anti-EGFRvIII CAR downstream of a Lox-Stop-Lox cassette inserted into the Rosa26 locus... Our data provide the first comprehensive comparison of CAR-expressing immune cell subsets in an immune-competent glioma model. This platform enables precise functional assessment and supports the development of rational combination strategies—most notably, the synergy between CAR-T and CAR-NKT cells—to improve GBM immunotherapy."

Immune cell • IO biomarker • Brain Cancer • Glioblastoma • Glioma • Oncology • Solid Tumor • CD4 • CSF2 • IFNG

Comparative evaluation of CAR-expressing T-, NK-, NKT-cells, and macrophages in an immunocompetent mouse glioma model. (PubMed, Neurooncol Adv) - "Crossing with mice transgenic for Vav-Cre allowed the expression of anti-EGFRvIII CAR in all hematopoietic cells...These data provide a valuable basis as to which immune cells can mediate effective anti-glioma response in an immuno-competent glioma environment. Our data also suggest that a combination of CAR-T and CAR-NKT-cells may represent a promising therapeutic strategy."

IO biomarker • Journal • Preclinical • Brain Cancer • Glioma • Oncology • Solid Tumor

Development of a Transgenic Mouse Model Enabling Comparative Analysis of chimeric antigen receptor (CAR)-Expressing Immune Cell Populations for Cancer Immunotherapy (SNO 2023) - "As the extension of the approach, we crossed the EGFRvIII-CAR Tg mice with mice carrying Vav-Cre, which allowed the expression of anti-EGFRvIII CAR in all hematopoietic cells...This transgenic mouse model offers rigorous and reproducible evaluations of CAR-expressing hematopoietic cells. Furthermore, the model provides a platform for developing combination therapies, such as CAR-T plus CAR-NKT or CAR-T plus CAR-NK cells, with potential implications for enhanced cancer treatment strategies."

Immune cell • IO biomarker • Preclinical • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • CD4 • IFNG • IL17A • IL2 • IL4 • TNFA

INTERCEPT: Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM (clinicaltrials.gov) - P1; N=2; Terminated; Sponsor: Gary Archer Ph.D.; N=24 ➔ 2

Enrollment change • Brain Cancer • Glioblastoma • Gliosarcoma • Oncology • Sarcoma • Solid Tumor • PCR

Kite Pharma: Corporate Presentation (Kite Pharma) - Anticipdated data from P1/2 trial (NCT01454596) for glioblastoma in 2016

Anticipated P1/2 data • Oncology

INTERCEPT: Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Gary Archer Ph.D.; Suspended ➔ Recruiting

Clinical • Enrollment open

INTERCEPT: Intracerebral EGFR-vIII CAR-T Cells for Recurrent GBM (clinicaltrials.gov) - P1; N=24; Suspended; Sponsor: Gary Archer Ph.D.; Recruiting ➔ Suspended

Clinical • Trial suspension

CAR T Cell Receptor Immunotherapy Targeting EGFRvIII for Patients With Malignant Gliomas Expressing EGFRvIII (clinicaltrials.gov) - P1/2; N=18; Completed; Sponsor: National Cancer Institute (NCI); Recruiting ➔ Completed; N=107 ➔ 18; Trial completion date: Dec 2029 ➔ Jan 2019; Trial primary completion date: Dec 2028 ➔ Jan 2019

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date